Literature DB >> 22365514

Prognostic factors and staging for soft tissue sarcomas: an update.

Natalie B Jones1, Hans Iwenofu, Thomas Scharschmidt, William Kraybill.   

Abstract

Soft tissue sarcoma (STS) staging is a constantly evolving process. Grading is still of utmost importance and has been adapted into a three-tier system. The STS most difficult to categorize are those with uncertain malignant potential, such as solitary fibrous tumors, gastrointestinal stromal tumors, and glomus tumors, some of which have developed completely separate staging systems and may not even be considered sarcomas. Beyond the current TNM staging system, a multitude of prognostic factors for STS will continue to be discovered and ultimately incorporated into future revisions of the staging system. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22365514     DOI: 10.1016/j.soc.2011.12.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  8 in total

1.  Pleomorphic Sarcoma in a Patient with Osteopetrosis.

Authors:  Kevin McGill; Daria Motamedi; Nima Azimi; Andrew Horvai; Richard O'Donnell
Journal:  J Radiol Case Rep       Date:  2020-07-31

2.  A review of controversies in the management of soft tissue sarcomas.

Authors:  S V S Deo; N M L Manjunath; N K Shukla
Journal:  Indian J Surg       Date:  2012-06-20       Impact factor: 0.656

3.  Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Authors:  R L Jones; G D Demetri; S M Schuetze; M Milhem; A Elias; B A Van Tine; J Hamm; S McCarthy; G Wang; T Parekh; R Knoblauch; M L Hensley; R G Maki; S Patel; M von Mehren
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

4.  Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology.

Authors:  Melike Ozcelik; Mesut Seker; Emrah Eraslan; Sinan Koca; Dogan Yazilitas; Ozlem Ercelep; Ersin Ozaslan; Serap Kaya; Ilhan Hacibekiroglu; Serkan Menekse; Asude Aksoy; Burcu Yapar Taskoylu; Umut Varol; Erkan Arpaci; Aydin Ciltas; Berna Oksuzoglu; Nurullah Zengin; Mahmut Gumus; Mehmet Aliustaoglu
Journal:  Tumour Biol       Date:  2015-11-10

5.  Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.

Authors:  Jordan Amdahl; Stephanie C Manson; Robert Isbell; Ayman Chit; Jose Diaz; Lily Lewis; Thomas E Delea
Journal:  Sarcoma       Date:  2014-06-12

6.  A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.

Authors:  Michael J Wagner; Leo Ismaila Amodu; Mei Sheng Duh; Caroline Korves; Franco Solleza; Stephanie C Manson; José Diaz; Maureen P Neary; George D Demetri
Journal:  BMC Cancer       Date:  2015-03-25       Impact factor: 4.430

7.  Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively.

Authors:  Marcelo Campos; Silvana Gisele Pegorin DE Campos; Guilherme Gomes Ribeiro; Flávia Coltri Eguchi; Sandra Regina Morini DA Silva; Cleyton Zanardo DE Oliveira; Allini Mafra DA Costa; Emílio Carlos Curcelli; Marcos Ceita Nunes; Valter Penna; Adhemar Longatto-Filho
Journal:  Oncol Lett       Date:  2013-03-05       Impact factor: 2.967

8.  Nuclear DNA-Content in Mesenchymal Lesions in Dogs: Its Value as Marker of Malignancy and Extent of Genomic Instability.

Authors:  Kim M Boerkamp; Gerard R Rutteman; Marja J L Kik; Jolle Kirpensteijn; Christoph Schulze; Guy C M Grinwis
Journal:  Cancers (Basel)       Date:  2012-12-03       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.